PetIQ logo
PetIQ PETQ

Annual report 2023
added 02-29-2024

report update icon

PetIQ Cash Flow 2011-2025 | PETQ

Annual Cash Flow PetIQ

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

61.9 M 48 M 23.8 M -4.6 M 20.8 M -12.4 M 5.88 M -926 K -6.42 M - - - -

Depreciation & Amortization

44.5 M 35.5 M 39.3 M 27.5 M 16.5 M 12.5 M 3.61 M 4.07 M 3.14 M - - - -

Accounts Payables

139 M 113 M 55.1 M 68.1 M 51.5 M 54.8 M 14.2 M - - - - - -

Accounts Receivables

143 M 118 M 114 M 103 M 71.4 M 45 M 21.8 M - - - - - -

Total Inventories

159 M 143 M 96.4 M 97.8 M 79.7 M 92.1 M 44.1 M - - - - - -

All numbers in USD currency

Quarterly Cash Flow PetIQ

2023-Q3 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -872 K -65.4 M -45.4 M - 10.5 M -46.2 M -57.4 M - 13.8 M -42.5 M -68.6 M - -8.6 M -18.1 M -18.2 M - -13.3 M -8.85 M -38.4 M - 11 M -6.99 M -16.9 M - -1.34 M - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

10.9 M - 3.58 M 17.7 M 8.97 M - 28.9 M 20.4 M 12.4 M - 18.9 M 11.2 M 5.47 M - 11 M 6.06 M 3.09 M - 8.93 M 5.71 M 2.52 M - 2.72 M 1.69 M 851 K - 2.88 M - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

113 M - 73.4 M 81.1 M 129 M 55.1 M 62.5 M 61.7 M 101 M 68.1 M 68.1 M 68.1 M 68.1 M 51.5 M 51.5 M 51.5 M 51.5 M 54.8 M 54.8 M 54.8 M 54.8 M 14.2 M 14.2 M 14.2 M 14.2 M 9.33 M 9.33 M - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

152 M - 125 M 169 M 179 M 114 M 124 M 160 M 175 M 103 M 103 M 103 M 103 M 71.4 M 71.4 M 71.4 M 71.4 M 45 M 45 M 45 M 45 M 21.8 M 21.8 M 21.8 M 21.8 M 17.2 M 17.2 M - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

128 M - 147 M 160 M 168 M 96.4 M 108 M 118 M 131 M 97.8 M 97.8 M 97.8 M 97.8 M 79.7 M 79.7 M 79.7 M 79.7 M 92.1 M 92.1 M 92.1 M 92.1 M 44.1 M 44.1 M 44.1 M 44.1 M 34.2 M 34.2 M - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company PetIQ, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Drug manufacturers sector

Issuer Price % 24h Market Cap Country
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 1.7 50.0 % $ 183 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.24 13.51 % $ 1.69 B canadaCanada
Assertio Holdings Assertio Holdings
ASRT
$ 0.77 -1.79 % $ 54.7 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 5.36 17.8 % $ 86.3 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Emergent BioSolutions Emergent BioSolutions
EBS
$ 11.46 -2.22 % $ 587 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
$ 10.97 0.18 % $ 36.7 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
$ 21.38 -0.05 % $ 2.03 B franceFrance
Evolus Evolus
EOLS
$ 6.99 1.09 % $ 433 M usaUSA
Harrow Health Harrow Health
HROW
$ 47.18 -7.67 % $ 1.54 B usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 1.67 11.33 % $ 29.2 M chinaChina
cbdMD cbdMD
YCBD
$ 1.18 87.31 % $ 5.09 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.95 -0.93 % $ 2.54 B canadaCanada
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.88 14.72 % $ 402 M canadaCanada
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 2.61 4.99 % $ 36.7 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 4.83 1.15 % $ 636 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.28 2.14 % $ 1.22 B usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.12 -1.67 % $ 124 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 13.13 -2.23 % $ 1.8 B usaUSA
ProPhase Labs ProPhase Labs
PRPH
$ 0.12 -15.26 % $ 1.9 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 0.93 -2.37 % $ 21.7 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 2.19 24.01 % $ 3.37 M canadaCanada
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 0.64 -0.02 % $ 30.6 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 5.85 -0.34 % $ 239 M usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 3.59 -3.37 % $ 4.46 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Tilray Tilray
TLRY
$ 11.86 40.68 % $ 7.33 B canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.79 -2.72 % $ 18.7 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Veru Veru
VERU
$ 2.45 -4.3 % $ 330 M usaUSA
Viatris Viatris
VTRS
$ 11.63 0.3 % $ 14.1 B usaUSA